At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Randomized Study to Evaluate the Safety and Efficacy of Prochymal® (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) For the Treatment of Acute GVHD in Patients Who Receive Allogeneic Hematopoietic Stem Cell Transplantation
In Brief
A Phase 2 clinical trial evaluating Prochymal® - 2 Million cells/kg, Prochymal®- 8 Million cells/kg, and 5 other interventions for Graft Vs Host Disease. Completed, enrolled 32 participants across 9 sites.
Detailed Summary
To establish the safety and efficacy of two dose levels of ex-vivo cultured adult human mesenchymal stem cells (hMSCs) (Prochymal®) in participants experiencing acute GVHD, Grades II-IV, post hematopoietic stem cells (HSC) transplant.
Study Details
Timeline
Interventions
2 million hMSCs/kg actual body weight, IV on study Days 1 and 4
8 million hMSCs/kg actual body weight IV on study Days 1 and 4
Methylprednisolone 2 mg/kg administered intravenously.
Prednisone 2.5 mg/kg administered orally.
Administered as prescribed by the caregiver.
Administered as prescribed by the caregiver.
Administered as prescribed by the caregiver.